Flexible Ureteroscopy With a Flexible and Navigable Suction Ureteral Access Sheath Versus Mini-Percutaneous Nephrolithotomy for 1-2 cm Lower Pole Kidney Stones
Studying Photosensitive occipital lobe epilepsy
Last synced from ClinicalTrials.gov
Key facts
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Intervention
- Flexible ureteroscopy with FANS(procedure)
- Enrollment
- 640 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2025 – 2026
Study locations (1)
- The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Collaborators
Shengjing Hospital · The Third Xiangya Hospital of Central South University · Saint Petersburg State University Hospital · Fortune Urology Clinic · Zhongda Hospital · Tongji Hospital · The First Affiliated Hospital Hengyang Medical School · First Affiliated Hospital of Ningbo University · The Sixth Affiliated Hospital of Guangzhou Medical University · The First Affiliated Hospital of Xiamen University · Dehong People's Hospital · People's Hospital of Nanhai District, Foshan · Huadu District People's Hospital of Guangzhou · Jiangmen Central Hospital · Baoshan No.2 People's Hospital · Guizhou Provincial People's Hospital · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Tianjin Medical University Second Hospital · Ankara University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07159035 on ClinicalTrials.govOther trials for Photosensitive occipital lobe epilepsy
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07114653The Role of POLE Mutation in High Risk Endometrial Cancer.Far Eastern Memorial Hospital
- RECRUITINGNANCT06898216Steerable vs Conventional FANS for <2cm Lower Pole Stone Treatment: SCULPT TrialThe First Affiliated Hospital of Guangzhou Medical University
- ENROLLING BY INVITATIONNCT06409039POLE-END REAL LIFE: Endometrial Cancer Early Stages I-II and Advanced Stages III and IV Evaluation of POLE as a Prognostic Factor. Participants Are Women >= 18 Years Old, With the Pole MutationAzienda Ulss 2 Marca Trevigiana
- RECRUITINGPHASE2NCT05640999Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPERCanadian Cancer Trials Group
- RECRUITINGNANCT05388227Pole Walking Intervention in Retirement CommunitiesUniversity of Saskatchewan
- ACTIVE NOT RECRUITINGPHASE2NCT02912572Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial CancerDana-Farber Cancer Institute